Depolarization controls TRAIL-sensitization and tumor-selective killing of cancer cells: crosstalk with ROS

Yoshihiro Suzuki-Karasaki1,2*, Miki Suzuki-Karasaki3, Mayumi Uchida3 and Toyoko Ochiai3

1 Division of Physiology, Department of Biomedical Sciences, Nihon University School of Medicine, Tokyo, Japan
2 Innovative Therapy Research Group, Nihon University Research Institute of Medical Science, Tokyo, Japan
3 Department of Dermatology, Nihon University Surugadai Hospital, Tokyo, Japan

Reviewed by:
Olivier Micheau, Institut National de la Santé et de la Recherche Médicale, France
Evzen Krepela, Charles University in Prague, Czech Republic

*Correspondence:
Yoshihiro Suzuki-Karasaki, Division of Physiology, Department of Biomedical Sciences, Nihon University School of Medicine, 30-1 Oyaguchikami-machi, Itabashi-ku, Tokyo 173-8610, Japan
email: suzuki.yoshihiro@nihon-u.ac.jp

CONTRIBUTION

CONTRIBUTION

INTRODUCTION

Despite remarkable progress in cancer biology and treatment over the past 30 years, malignant neoplasms are still highly threatening diseases for humans, as they are frequently resistant to traditional chemotherapy, radiotherapy, and immunotherapy with a poor prognosis. Conventional genotoxic anti-cancer drugs target the proliferative advantage of tumor cells over normal cells. This kind of approach lacks the selectivity of treatment to cancer cells, because most of the targeted pathways are essential for the survival of normal cells. As a result, traditional cancer treatments are often limited by undesirable damage to normal cells (side-effects). Ideal anti-cancer drugs are expected to be highly effective against malignant tumor cells with minimal cytotoxicity toward normal cells. Such selective killing can be achieved by targeting pathways essential for the survival of cancer cells, but not normal cells. As cancer cells are characterized by their resistance to apoptosis, selective apoptosis induction is a promising approach for selective killing of cancer cells. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising tumor-selective anti-cancer drug. However, the congenital and acquired resistance of some cancer cell types, including malignant melanoma cells, currently impedes effective TRAIL therapy, and an innovative approach that can override TRAIL resistance is urgently required. Apoptosis is characterized by cell shrinkage caused by disruption of the maintenance of the normal physiological concentrations of K⁺ and Na⁺ and intracellular ion homeostasis. The disrupted ion homeostasis leads to depolarization and apoptosis. Recent evidence suggests that depolarization is an early and prerequisite event during TRAIL-induced apoptosis. Moreover, diverse natural products and synthetic chemicals capable of depolarizing the cell membrane exhibit tumor-selective killing and TRAIL-sensitizing effects. Here, we discuss the role of depolarization in selective killing of cancer cells in connection with the emerging concept that oxidative stress is a critical mediator of mitochondrial and endoplasmic reticulum dysfunctions and serves as a tumor-selective target in cancer treatment.

Keywords: depolarization, ROS, TRAIL, tumor-selective killing, sensitization, apoptosis, oxidative stress, endoplasmic reticulum stress

Abbreviations: AIF, apoptosis-inducing factor; ANT, adenine nucleotide translocator; Apaf-1, apoptotic peptidase activating factor 1; ATF6, activating transcription factor 6; DADS, diallyl disulfide; DATS, diallyl trisulfide; DCFH-DA, 2′,7′-dichlorodihydrofluorescein diacetate; DcR, decoy receptor; DHE, dihydroethidium; DR, death receptor; ∆Ψm, mitochondrial membrane potential; EC, endothelial cell; eIF2, eukaryotic initiation factor-2; ER, endoplasmic reticulum; ERS, endoplasmic reticulum stress; ETC, electron transport chain; FasL, Fas ligand; GPx7, glucose-related protein 78; IMM, inner mitochondrial membrane; IP3, inositol-1,4,5-triphosphate; IRE1, inositol requiring enzyme 1; JNK, Jun-N-terminal kinase; KCC, calcium-dependent K⁺; KcsA, voltage-dependent K⁺; mAbs, monoclonal antibodies; MHP, mitochondrial hyperpolarization; MMD, mitochondrial membrane depolarization; MnTBaP, Mn(III)tetrakis(4-benzoic acid)porphyrin chloride; MPT, mitochondrial permeability transition; mPTP, mitochondrial permeability transition pore; mROS, mitochondrial reactive oxygen species; NAC, N-acetyl-L-cysteine; NAO, 10-N-acylacylglucosaminidase; NSCLC, non-small cell lung cancer; OXPHOS, oxidative phosphorylation; PARs, pro-apoptotic receptor agonists; PEITC, β-phenylethyl isothiocyanate; PFK, phosphofructokinase; PKM, plasma membrane depolarization; rh, recombinant human; ROS, reactive oxygen species; siRNA, small interfering RNA; SMAC, second mitochondrial activator of caspases; SOD, superoxide dismutase; XBP-1, X-box-binding protein-1; XIAP, X-linked inhibitor of apoptosis protein.

Conventional genotoxic anti-cancer drugs target the proliferative advantage of tumor cells over normal cells. This kind of approach lacks the selectivity of treatment to cancer cells, because most of the targeted pathways are essential for the survival of normal cells. As a result, traditional cancer treatments are often limited by undesirable damage to normal cells (side-effects). Ideal anti-cancer drugs are expected to be highly effective against malignant tumor cells with minimal cytotoxicity toward normal cells. Such selective killing can be achieved by targeting pathways essential for the survival of cancer cells, but not normal cells. As cancer cells are characterized by their resistance to apoptosis, selective apoptosis induction is a promising approach for selective killing of cancer cells. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising tumor-selective anti-cancer drug. However, the congenital and acquired resistance of some cancer cell types, including malignant melanoma cells, currently impedes effective TRAIL therapy, and an innovative approach that can override TRAIL resistance is urgently required. Apoptosis is characterized by cell shrinkage caused by disruption of the maintenance of the normal physiological concentrations of K⁺ and Na⁺ and intracellular ion homeostasis. The disrupted ion homeostasis leads to depolarization and apoptosis. Recent evidence suggests that depolarization is an early and prerequisite event during TRAIL-induced apoptosis. Moreover, diverse natural products and synthetic chemicals capable of depolarizing the cell membrane exhibit tumor-selective killing and TRAIL-sensitizing effects. Here, we discuss the role of depolarization in selective killing of cancer cells in connection with the emerging concept that oxidative stress is a critical mediator of mitochondrial and endoplasmic reticulum dysfunctions and serves as a tumor-selective target in cancer treatment.

Keywords: depolarization, ROS, TRAIL, tumor-selective killing, sensitization, apoptosis, oxidative stress, endoplasmic reticulum stress

Abbreviations: AIF, apoptosis-inducing factor; ANT, adenine nucleotide translocator; Apaf-1, apoptotic peptidase activating factor 1; ATF6, activating transcription factor 6; DADS, diallyl disulfide; DATS, diallyl trisulfide; DCFH-DA, 2′,7′-dichlorodihydrofluorescein diacetate; DcR, decoy receptor; DHE, dihydroethidium; DR, death receptor; ∆Ψm, mitochondrial membrane potential; EC, endothelial cell; eIF2, eukaryotic initiation factor-2; ER, endoplasmic reticulum; ERS, endoplasmic reticulum stress; ETC, electron transport chain; FasL, Fas ligand; GPx7, glucose-related protein 78; IMM, inner mitochondrial membrane; IP3, inositol-1,4,5-triphosphate; IRE1, inositol requiring enzyme 1; JNK, Jun-N-terminal kinase; KCC, calcium-dependent K⁺; KcsA, voltage-dependent K⁺; mAbs, monoclonal antibodies; MHP, mitochondrial hyperpolarization; MMD, mitochondrial membrane depolarization; MnTBaP, Mn(III)tetrakis(4-benzoic acid)porphyrin chloride; MPT, mitochondrial permeability transition; mPTP, mitochondrial permeability transition pore; mROS, mitochondrial reactive oxygen species; NAC, N-acetyl-L-cysteine; NAO, 10-N-acylacylglucosaminidase; NSCLC, non-small cell lung cancer; OXPHOS, oxidative phosphorylation; PARs, pro-apoptotic receptor agonists; PEITC, β-phenylethyl isothiocyanate; PFK, phosphofructokinase; PKM, plasma membrane depolarization; rh, recombinant human; ROS, reactive oxygen species; siRNA, small interfering RNA; SMAC, second mitochondrial activator of caspases; SOD, superoxide dismutase; XBP-1, X-box-binding protein-1; XIAP, X-linked inhibitor of apoptosis protein.

mROS, mitochondrial reactive oxygen species; NAC, N-acetyl L-cysteine; NAO, 10-N-acrylacylglucosaminidase; NSCLC, non-small cell lung cancer; OXPHOS, oxidative phosphorylation; PARs, pro-apoptotic receptor agonists; PEITC, β-phenylethyl isothiocyanate; PFK, phosphofructokinase; PKM, plasma membrane depolarization; rh, recombinant human; ROS, reactive oxygen species; siRNA, small interfering RNA; SMAC, second mitochondrial activator of caspases; SOD, superoxide dismutase; SUR, sulfonylurea receptor; TEA, tetrathylenelammonium; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand; TRAIL-R, TNF-related apoptosis-inducing ligand and receptor; TRPV1, transient receptor potential vanilloid 1; UPR, unfolded protein response; VDAC, voltage-dependent anion channel; VEGF, vascular endothelial growth factor; XBP-1, X-box-binding protein-1; XIAP, X-linked inhibitor of apoptosis protein.
cells are characterized by their resistance to apoptosis, selective apoptosis induction is a promising approach for selective killing of cancer cells. A growing list of natural products and synthetic chemicals exhibit tumor-selective killing effects (Tables 1 and 2). Under optimal conditions, they exhibit considerable cytotoxicity toward malignant cells, while sparing non-transformed cells. In addition, when applied at non-toxic concentrations, some of them can sensitize cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) cytotoxicity (Table 3). In fact, overlapping mechanisms appear to be involved in the tumor-selective killing and TRAIL-sensitizing effects, and the generation of intracellular reactive oxygen species (ROS) is the most common cellular event documented in the literature. An emerging view is that owing to their active metabolism and oscillatory stimulation, most cancer cells exhibit elevated ROS generation that makes them more vulnerable than normal cells to additional oxidative stress, and that such vulnerability can be exploited to selectively kill these cells. We will discuss this concept in more detail later. Although diverse natural and synthetic chemical compounds have been shown to possess selective killing effects, this review focuses on TRAIL, because TRAIL and its related substances are promising tumor-selective anti-cancer drugs that are currently undergoing clinical trials.

**TRAIL AND CANCER CELL DEATH**

Tumor necrosis factor-related apoptosis-inducing ligand is a member of the TNF cytokine family. It binds to several distinct receptors, death receptor (DR) 4/TRAIL receptor 1 (TRAIL-R1), DR5/TRAIL-R2, TRAIL-R3, and TRAIL-R4 (1). Both DR4 and DR5 contain an intracellular death domain that is essential for the induction of apoptosis following receptor ligation. In contrast, despite their binding to TRAIL, neither TRAIL-R3 nor TRAIL-R4 mediates apoptosis owing to a complete or partial lack of the intracellular death domain. These receptors are regarded as decoy receptors (DrRs) (1, 2). TRAIL activates the extrinsic apoptotic pathway. Binding of TRAIL to DR4/DR5 induces their oligomerization and conformational changes in their death domains, resulting in the formation of a death-inducing signaling complex and subsequent activation of the initial caspase, caspase-8. In turn, activated caspase-8 activates the effector caspases, caspase-3/6/7 that execute the apoptotic process (3, 4). Activation of caspase-8 is also linked to the intrinsic (mitochondrial) apoptotic pathway. Activated caspase-8 can cleave and activate the pro-apoptotic Bcl-2-family molecule Bid. In turn, truncated Bid activates other Bcl-2-family molecules, Bax and Bak, resulting in their oligomerization and the formation of megachannels in the outer mitochondrial membrane (OMM). The release of cytochrome c through these Bax/Bak megachannels into the cytosol induces assembly of the apoptosome, representing the activation-platform for another initial caspase, caspase-9. Activated caspase-9 also promotes the activation of caspase-3/6/7, thereby providing a positive loop for caspase activation (3). Unlike TNF-α, TRAIL has been shown to induce apoptosis in cancer cells with minimal cytotoxicity toward non-transformed cells (4), although under certain circumstances, it enhances the cytotoxicity of several drugs to hepatocytes/liver and mast cells (5–9). Thus, TRAIL is a promising agent in cancer treatment with high selectivity. However, different cancer cell types such as malignant melanoma, glioma, and non-small cell lung cancer (NSCLC) cells are resistant to TRAIL treatment despite expressing DRs on their cell surface. Moreover, TRAIL-responsive tumors acquire a resistant phenotype that renders TRAIL therapy ineffective (10). Therefore, overcoming TRAIL resistance is necessary for effective TRAIL therapy, and small molecules that can potentiate TRAIL effectiveness are urgently required. Recently, much progress has been made in therapeutic intervention with TRAIL-related substances. Recombinant human TRAIL (rhTRAIL) or agonist monoclonal antibodies (mAbs) against DR4/DR5, collectively referred to as pro-apoptotic receptor agonists (PARAs), have been subjected to clinical trials for a variety of cancer cell types, including malignant melanoma and NSCLC cells. In addition, diverse chemical substances including ABT-737 and SM-164 are expected to potentiate the intrinsic death pathway by antagonizing natural inhibitors such as FLICE inhibitory protein, Bcl-2, Mcl-1, and survivin (11). Some recent clinical trials have demonstrated the safety and efficiency of combined treatments with PARAs and conventional genotoxic drugs, while the results of other clinical trials were disappointing and showed only modest effectiveness. PARAs such as dulanermin (rhTRAIL), mapatumumab (anti-DR4 mAb), conatumumab, CS-1008, or PRO95780 (anti-DR5 mAb), in combination with paclitaxel, carboplatin, or bevacizumab [anti-vascular endothelial growth factor (VEGF) mAb] were tested for their effects toward NSCLC patients in a randomized phase II trial, but showed only modest effects (11). Thus, induction of apoptosis by the intrinsic pathway does not appear to be a suitable target in the treatment of TRAIL-resistant cancer cells.

**DUAL FUNCTION OF DEPOLARIZATION IN THE REGULATION OF APOPTOSIS**

Apoptosis is a fundamental physiological process characterized by the loss of cell volume (cell shrinkage), chromatin condensation, and internucleosomal DNA fragmentation. Cell shrinkage is a hallmark of apoptosis, which is caused by disruption of the maintenance of normal physiological concentrations of K+ and Na+ and intracellular ion homeostasis (12, 13). Loss of these monovalent ions has been reported to facilitate the loss of cell volume (apoptotic volume decrease) and caspase-3 activation (13). Cell shrinkage requires ion transport activity across the cell membrane, including Cl− and K+ channels. Impairment of ion channels or transporters responsible for Na+, K+, Cl−, and Ca2+ can disrupt intracellular ion homeostasis and lead to cell membrane depolarization and apoptosis. In fact, depolarization has been shown to be an early event in the apoptosis induced by diverse agents, including Fas, rotenone, and arsenic trioxide (14–16), and is considered to play an important pro-apoptotic role. In contrast, depolarization has also been shown to exhibit anti-apoptotic effects. Various membrane-depolarizing agents, including ouabain, tetraethylammonium (TEA), and veratridine, protect Purkinje cells against apoptosis (17). In addition, K+ loading and several K+ channel inhibitors protect various human tumor cells against staurosporin-induced apoptosis. Thus, depolarization can act in both pro-apoptotic and anti-apoptotic manners depending on the cell types and apoptotic stimuli involved. There is no general model that can depict the dual functions of depolarization.
Table 1 | Natural products with tumor-selective cytotoxicity.

| Compounds         | Cancer cells         | Normal cells          | Mode of cell death | ROS | Mechanisms of cell death                                                                 | Reference |
|-------------------|----------------------|-----------------------|--------------------|-----|------------------------------------------------------------------------------------------|-----------|
| Wogonin           | Leukemia             | Lymphocytes           | Apoptosis          | H₂O₂| H₂O₂-PLC-Ca²⁺ overload-MMD-intrinsic death pathway                                       | Baumann et al. (103) |
|                   |                      |                       |                    |     | Involvement of VDCC in the Ca²⁺ response                                                  |           |
| Wogonin           | Hepatoma (HepG2)     | Hepatic cells (LO2)   | Apoptosis          | O₂⁻, H₂O₂| ROS target Ca²⁺ release from ER (IP₃-sensitive channels)-Ca²⁺ overload MMD, AIF release     | Wei et al. (104) |
|                   |                      |                       |                    |     | Blockade by Bcl-2 (intrinsic death pathway)                                               |           |
| Wogonin           | Glioma               | Astrocytes            | Apoptosis          | H₂O₂| Intrinsic death pathway                                                                    | Tsai et al. (105) |
|                   |                      |                       |                    |     | O₂⁻, H₂O₂ ROS target Ca²⁺ release from ER (IP₃-sensitive channels)-Ca²⁺ overload MMD, AIF release |           |
| EGCG              | Chondrosarcoma       | Chondrocytes          | Apoptosis          | O₂⁻, H₂O₂| Upregulation of Bax, Bak Downregulation of Bcl-2, Bcl-xL MMD, ASK₁-p38/JNK pathway        | Yang et al. (106) |
| Capsaicin         | Leukemia             | T lymphocytes         | Apoptosis          | O₂⁻(outside of mitochondria) | Plasma membrane electron transport system MMD Ca²⁺ mobilization (TRPV1) | Macho et al. (107) |
| Capsaicin         | Pancreatic cancer    | HPDE-6                | Apoptosis          | H₂O₂| Complex I and III-mediated H₂O₂ MMD Cardiolipin oxidation Intrinsic death pathway         | Pramanik et al. (108) |
| Pancratistatin    | Neuroblastoma        | Fibroblasts           | Apoptosis          | H₂O₂| Intrinsic death pathway                                                                    | McLachlan et al. (109) |
| Pancratistatin    | Metastatic prostate cancer | Fibroblasts         | Apoptosis          | H₂O₂| Intrinsic death pathway                                                                    | Griffin et al. (110) |
| Pancratistatin    | Colorectal carcinoma | Fibroblasts           | Apoptosis          | Not determined| Bax, p53, caspase-independent death pathway MMD mtDNA-depleted cells are resistant | Griffin et al. (111) |
| Piperlongumine    | Breast cancer, lung cancer, osteosarcoma | Fibroblasts, epithelial cells | Apoptosis          | H₂O₂, NO| Transformation-associated ROS p53-independent Glutathione transferase-π-CBRI | Raj et al. (112) |
| Diallyl sulfide (DAS)/diallyl disulfide (DADS) | Neuroblastoma        | Neurons               | Apoptosis          | Not determined| Intrinsic death pathway                                                                    | Karmakar et al. (113) |
|                  |                      |                       |                    |     | Ca²⁺ mobilization Increase in Bax/Bcl-2 ratio, Smac/Diablo release                           |           |
|                  |                      |                       |                    |     | Calpain activation, ICAD cleavage                                                         |           |
| Resveratrol       | Prostate, colon cancer, hepatoma | Fibroblasts          | Apoptosis          | Not determined| Intrinsic death pathway                                                                    | Gosslau et al. (114) |
| Resveratrol       |                      |                       |                    |     | Increase in Bax/Bcl-2 ratio, p53, Bax protein level Perinuclear aggregation of mitochondria |           |
| Resveratrol       |                      |                       |                    |     |                                                     |           |
| Bezielle          | Breast cancer        | Epithelial cells      | Apoptosis          | Mitochondrial O₂⁻, H₂O₂| ROS-DNA damage-PARP hyperactivation-NAD/ATP depletion-glycolysis inhibition-energy collapse OXPHOS inhibition | Chen et al. (115) |
| bis-Dehydroxy-     | Colorectal carcinoma | Fibroblasts           | Apoptosis          | Not determined| Mitochondria-dependent apoptosis Caspase-7/8/9 ERS-induced autophagy                      | Basile et al. (116) |
| Curcumin          |                      |                       | Autophagy          |     |                                                     |           |
**Table 2 | Synthetic compounds with tumor-selective cytotoxicity.**

| Compounds          | Cancer cells | Normal cells | Mode of cell death | ROS            | Mechanisms of cell death                                                                 | Reference |
|--------------------|--------------|--------------|--------------------|----------------|------------------------------------------------------------------------------------------|-----------|
| Glitazones         | Glioma       | Astrocytes   | Apoptosis          | $O_2^-$, NO, ONOO$^-$ | MMD, Reduction in mitochondrial pH, ETC complex I                                          | Pérez-Ortiz et al. (117) |
| Salinomycin        | Prostate, breast cancer | Fibroblasts | Autophagy (cell protective) Apoptosis Necrosis | Not determined | Increased mitochondrial mass MMD, MHP (subpopulation) Caspase-3, -8, -9 ATP decrease Mitochondrial fragmentation Mitophagy Mitotosis | Jangamreddy et al. (119) |
| Rosiglitazone      | Glioma       | Astrocytes   | Apoptosis          | $H_2O_2$       | PPAR-y-independent MMD, Inhibition by etselen, NAC                                        | Pérez-Ortiz et al. (119) |
| GYY4137            | Hepatoma, leukemia, colorectal carcinoma, etc. | Fibroblasts | Apoptosis          | (H$_2$S)       | Intrinsic death pathway                                                                 | Lee et al. (122) |

**Na$^+$–K$^+$-ATPase IS A KEY PLAYER CONNECTING DEATH LIGANDS, DEPOLARIZATION, AND APOPTOSIS**

The Na$^+$ pump Na$^+$–K$^+$-ATPase mediates the export of three Na$^+$ ions the import of two K$^+$ ions, thereby maintaining high K$^+$ and low Na$^+$ intracellular concentrations. Diverse apoptotic stimuli including anti-Fas, A23187, and thapsigargin have been shown to induce depolarization without repolarization in Jurkat cells (14). This response is rapid (1–2 h after stimulation) and observed in a time-dependent manner. Unlike the depolarization observed in electrically excited cells, this apoptosis-associated depolarization is rather sustained (observed for throughout at least 8 h, as the depolarization lacks repolarization. These effects can be accounted for inactivation of Na$^+$–K$^+$-ATPase protein and its activity. Persistent depolarization caused by impairment of Na$^+$–K$^+$-ATPase is also associated with other apoptotic stimuli such as the mitochondrial toxins rotenone and squamocin (15). The persistent depolarization is observed not only in human leukemia cells such as Jurkat cells and U937 cells but also in human primary T cells, although primary cells are more resistant than leukemia cells to the effect. The persistent depolarization is pro-apoptotic, because some cardic glycoside inhibitors of Na$^+$–K$^+$-ATPase such as ouabain and oleandrin, can sensitize human leukemia cells and NSCLC cells to apoptosis induced by anti-Fas, TRAIL, and mitochondrial toxins (14, 15, 18). These observations suggest that Na$^+$–K$^+$-ATPase is a key player connecting death ligands, depolarization, and apoptosis.

**ROLE OF DEPOLARIZATION IN TRAIL-INDUCED APOPTOSIS OF MALIGNANT TUMOR CELLS**

Our recent work has shown that persistent depolarization also occurs in the early stage of TRAIL-induced apoptosis in malignant tumor cells. TRAIL dose- and time-dependently induces robust depolarization in human malignant tumor cells, including melanoma, leukemia, and lung cancer cells after a time lag of 2-4 h (19, 20). In all tumor cell lines tested, the magnitude of depolarization is correlated with their sensitivity to TRAIL. Importantly, the depolarization appears to be a prerequisite event for TRAIL-induced apoptosis, because TRAIL induces minimal depolarization in normal melanocytes, to which it shows minimal cytotoxicity despite their substantial cell surface expression of DR4 and DR5 (19). The pro-apoptotic role of depolarization is supported by the finding that high K$^+$ loading sensitizes melanoma cells, but not melanocytes, to TRAIL. As ATP-sensitive K$^+$ (K$^+$ATP) channels mediate the eflux of intracellular K$^+$ into the cytosol, thereby promoting plasma membrane hyperpolarization, inhibition of these channels is expected to induce depolarization and show similar effects. In fact, selective inhibitors of K$^+$ATP channels such as glibenclamide and U37883A show similar TRAIL-sensitizing effects, while TEA, which mainly inhibits voltage-dependent K$^+$ ($K_v$) channels, is ineffective, suggesting a specific role of K$^+$ATP channels in the potentiation. In support of this view, the $K_v$ channel-specific inhibitor α-dendrotoxin, $K_{Ca}$ channel-specific inhibitor charybdotoxin, and mitochondrial K$^+$ATP channel inhibitor 5-hydroxydecanoate have no such effects in melanoma and leukemia cells (19–21). As discussed below, the depolarization-mediated potentiation of apoptosis is associated with activation of the mitochondrial apoptotic pathway and intracellular ROS generation. Consistent with this view, glibenclamide has been shown to exert antitumor activity in human gastric cancer cells through the intrinsic pathway and ROS generation. Since Na$^+$–K$^+$-ATPase seems to play a key role in controlling death...
Suzuki-Karasaki et al. Depolarization controls tumor-selective killing

Table 3 | Reactive oxygen species-generating TRAIL sensitizers.

| Compounds                  | Action                | Target cells          | Mode of cell death | ROS          | Mechanisms of sensitization                                      | Reference          |
|----------------------------|-----------------------|-----------------------|--------------------|--------------|---------------------------------------------------------------|--------------------|
| CCCP                       | OXPHOS uncoupler      | Colon carcinoma       | Apoptosis          | $O_2^-$      | Caspase-dependent MMD                                          | Izaradjene et al. (67) |
|                            |                       |                       |                    |              | ROS-dependent Bax and caspase-8 activation Inhibition by Bcl-2, XIAP |                    |
|                            |                       |                       |                    |              | Caspase-9-independent                                          |                    |
| LY303511                   | Inactive              | Neuroblastoma         | Apoptosis          | $H_2O_2$     | $H_2O_2$-induced JNK/ERK-mediated upregulation of DR4 and DR5 | Shenoy et al. (49)  |
|                            | LY294402 analog       |                       |                    |              |                                                               |                    |
| Selenium                   | Chemopreventive agent | Prostate cancer       | Apoptosis          | $O_2^-$      | $O_2^-$ mediated p53 Ser$_{15}$ Phosphorylation Bax increase and translocation | Hu et al. (123)    |
| Wogonin                    | Anti-cancer agent     | Prostate cancer       | Apoptosis          | $H_2O_2$     | $O_2^-$ mediated upregulation of p53 and Puma                | Lee et al. (50)     |
| KCl/U37883A/glibenclamide  | PMD                   | Melanoma, leukemia, lung cancer | Apoptosis          | Mitochondrial $O_2^-$ | PMD, MMD Upregulation of DR4 and DR5 ERS (XBP-1, caspase-12) | Suzuki et al. (19), Suzuki-Karasaki et al. (21) |
| DATS                       | Anti-cancer agent     | Melanoma              | Apoptosis          | $H_2O_2$, $O_2^-$ | Upregulation of DR4 and DR5 MMD, MMD ERS (XBP-1, caspase-12) | Murai et al. (22)   |
| $H_2O_2$                   | Membrane-permeable ROS| Melanoma              | Apoptosis          | Mitochondrial $O_2^-$ | Upregulation of DR4 and DR5 MMD, MMD ERS (XBP-1, caspase-12) | Tochigi et al. (23) |
| Rotenone, antymycin A, FCCP | OXPHOS inhibitor      | Melanoma, lung cancer | Apoptosis          | Mitochondrial $O_2^-$ | PMD, MMD                                                      | Inoue and Suzuki-Karasaki (20) |

ligand-induced depolarization and apoptosis, the enzyme may also be involved in the depolarization induced by TRAIL. However, it is noted that among these death ligands, only TRAIL exerts tumor-selective cytotoxicity. Nonetheless, cardiac glycoside Na$^+$–K$^+$-ATPase inhibitors such as oleandrin (18) and K$_{ATP}$ channel inhibitors share some biological effects including upregulation of DR4 and DR5. Thus, further studies are necessary to define the role of Na$^+$–K$^+$-ATPase in TRAIL-induced apoptosis in human cancer cells.

ROLE OF THE MITOCHONDRIAL DEATH PATHWAY IN THE EFFECTS OF DEPOLARIZATION

In addition to high K$^+$ and K$_{ATP}$ channel inhibitors, different natural and synthetic chemicals have recently been identified as powerful potentiators of TRAIL-induced apoptosis in malignant melanoma cells regardless of their diverse chemical structures and biological targets. These include diallyltrisulfide (DATS), a major garlic organosulfur compound (22), the cell-permeable oxidant $H_2O_2$ (23), and mitochondrial metabolic inhibitors such as rotenone, antymycin A, and FCCP (20). Moreover, when employed at higher concentrations and longer exposures, all of these chemicals kill malignant cells while sparing normal cells. Strikingly, all of these agents also can commonly induce robust depolarization prior to apoptosis, supporting a universal role for depolarization in the potentiation of TRAIL-induced apoptosis and tumor-selective killing. In contrast, agents that do not affect cell survival such as TEA, have no effect on DR5 expression, suggesting that upregulation of DR5 expression is a common target of these membrane-depolarizing agents for potentiating apoptosis. This view is also in agreement with previous studies demonstrating that amplification of TRAIL-induced apoptosis by diverse agents, including thapsigargin, tunicamycin, and 2-deoxy-d-glucose, is associated with upregulation of DR5 expression (24–26). The intrinsic mitochondrial pathway plays a crucial role in amplifying TRAIL-induced apoptosis, and collapse of the mitochondrial membrane potential ($\Delta \Psi_m$) is considered to be a hallmark of this pathway, although it remains a matter of debate whether this event is a cause or a result of permeabilization of the OMM (27, 28). Permeabilization of the OMM by pro-apoptotic Bcl-2 family proteins promotes the release of a number of apoptogenic factors, such as cytochrome c, endonuclease G, second mitochondrial activator of caspases (SMAC), Omi/HtrA2, and apoptosis-inducing
factor (AIF), from the inner mitochondrial membrane (IMM) space into the cytosol, and these apoptogenic proteins promote activation of the caspase cascade, thereby leading to apoptosis. Cytochrome c interacts with the apoptotic peptidase activating factor 1 (Apaf-1), leading to the formation of the multimeric apopotosome in the presence of ATP/dATP (28). The apopotosome acts as a platform for activation of the initiator caspase, caspase-9, which subsequently cleaves and activates the effector caspses, caspases-3 and -7. A cytochrome c-independent apoptosis pathway has also been defined, and this pathway requires proteins such as endonuclease G and AIF to carry out apoptosis. Although the molecular mechanisms underlying the OMM permeabilization are poorly understood, it is widely accepted that the mitochondrial permeability transition (MPT) pathway, which was originally defined as a sudden increase in IMM permeability to solutes with molecular masses of ~1,500 Da, is involved. It is now believed that opening of putative megachannels referred to as the mitochondrial permeability transition pores (mPTPs) plays pivotal roles (30, 31). mPTPs are high-conductance non-specific pores in the IMM composed of proteins that link the IMM and OMM. Several mitochondrial proteins localized in the IMM and OMM, such as voltage-dependent anion channels (VDACs), adenine nucleotide translocase (ANT), hexokinase, peripheral benzodiazepine receptors, and cyclophilin-D are thought to constitute the mPTP. Under physiological conditions, the proteins in the OMM and IMM that constitute mPTPs are thought to be in close proximity to one another and in a closed or low-conductance conformation, although mPTPs have not been isolated and the components of these complexes remain controversial (32–34). When an mPTP changes to an open conformation, water and solutes with molecular masses of up to 1,500 Da enter the mitochondrial matrix, resulting in osmotic swelling of the mitochondrion. It is thought that when multiple mPTPs open concurrently and extensive mitochondrial swelling takes place, physical disorganization of the OMM occurs and mitochondrial apoptogenic proteins are released, thereby triggering apoptosis (27). Hence, much attention has been paid to the potential role of mPTPs as a target for anti-cancer and chemopreventive agents (27, 28). TRAIL induces both ∆Ψm collapse and caspase-3/7 activation in melanoma and leukemia cells and the sensitization of TRAIL-induced apoptosis by membrane-depolarizing agents is associated with their enhancement, indicating the involvement of the intrinsic pathway. Although glibenclamide and U37883A are potent KATP channel inhibitors, glibenclamide targets sulfonlurea receptors (SURs) while U37883A is non-SUR drug. It is noted that glibenclamide and U37883A have different effects on TRAIL-induced cell death depending on TRAIL sensitivity. In TRAIL-resistant A375 melanoma cells, U37883A can potentiate TRAIL-induced cell death as rapidly as within 24 h, while glibenclamide is ineffective, despite considerable potentiation of TRAIL-induced ∆Ψm collapse and caspase-3/7 activation. This cell death is mainly caused by apoptosis. However, after 72 h of treatment, glibenclamide alone can induce considerable apoptotic and necrotic cell death and potentiates TRAIL effectiveness. However, both U37883A and glibenclamide can enhance apoptosis in TRAIL-sensitive Jurkat leukemia cells during the initial 24 h (20). Thus, these observations suggest that: (i) TRAIL and the two KATP channel inhibitors can induce different modes of cell death depending on the basal cellular sensitivity to TRAIL and experimental conditions such as exposure time, which is supported by the fact that substantial necrotic cell death is associated with the late cell death, but not the early cell death; (ii) SURs may play differential roles in the two modes of cell death in TRAIL-resistant cells; and (iii) activation of mitochondrial death pathway is insufficient for complete overriding of TRAIL resistance in malignant cells. This view coincides with the findings in clinical trials that the combined use of PARAs and other conventional chemotherapeutic drugs exhibit only modest effects toward TRAIL-resistant cancers, although they can induce substantial activation of the intrinsic death pathway (11). Consequently, the potentiation of TRAIL-induced apoptosis in TRAIL-resistant cancer cells by membrane-depolarizing agents may involve another cell death pathway.

**ROLE OF THE ENDOPLASMIC RETICULUM DEATH PATHWAY IN THE EFFECTS OF DEPOLARIZATION**

The emerging concept is that, besides mitochondria, the endoplasmic reticulum (ER) is another key player in the regulation of apoptosis induced by a variety of death stimuli, including TRAIL. Disparate perturbations in their normal ER functions, such as accumulation of unfolded or misfolded proteins, ER lipid imbalances or changes in the redox balance, or Ca2+ conditions in the ER lumen, trigger ER stress (ERS) (35–38). The cells then activate ERS responses, called the unfolded protein response (UPR), to alleviate the stress, but an excessive and prolonged UPR leads to apoptosis (36–38). The UPR involves transcription-dependent upregulation of ER-resident chaperones, and the ER chaperone glucose-related protein 78 (GRP78; also known as Bip) is thought to be a primary sensor in this response. Upon ERS, GRP78 dissociates from ER transmembrane proteins, such as inositol requiring enzyme 1 (IRE1) and activating transcription factor 6 (ATF6), to bind to unfolded or misfolded proteins, resulting in aggregation of the transmembrane proteins and their activation. Activated IRE1 splice the mRNA for X-box-binding protein-1 (XBP-1) to allow translation of the mature spliced form of XBP-1 protein, which acts as a transcription factor and mediates the transcriptional upregulation of numerous genes involved in ER function as well as TRAIL-R2 (25). In support of the role of ERS in TRAIL-induced apoptosis, TRAIL induces the splicing of XBP-1, and membrane-depolarizing agents including high K+ , U37883A (19, 21), DATS (22), H2O2 (23), and mitochondrial inhibitors such as antimycin A and FCCP (20) all commonly potentiate this effect, although none of these agents except H2O2 alone can induce the splicing. Only glibenclamide cannot potentiate TRAIL-induced XBP-1 activation, although it upregulates GRP78 expression in accordance with its minimal effect on TRAIL-induced cell death during the initial 24 h (19). These observations are interesting because GRP78 acts as an anti-apoptotic factor in the cells, since downregulation of GRP78 expression by small interfering RNA (siRNA) administration potentiates the apoptosis induced by diverse drugs including cisplatin, adriamycin (25), fenretinide [N-(4-hydroxyphenyl) retinamide], a synthetic derivative of retinoic acid, and bortezomib, a 26S proteasome inhibitor (39). Taken together, it is strongly suggested that pro-apoptotic ERS responses including GRP78 down-regulation, XBP-1 upregulation and processing are activated by
depolarization and play an important role in TRAIL-sensitization and tumor-selective killing.

**DUAL ROLE OF ROS IN APOPTOSIS**

Reactive oxygen species, such as superoxide anions (O$_2^•$–), H$_2$O$_2$, and hydroxyl radicals (•OH), are the products of normal metabolism in virtually all aerobic organisms. Low physiological levels of ROS function as second messengers in intracellular signaling and are required for normal cell function, while excessive ROS cause damage to multiple macromolecules, impair cell function, and promote apoptotic or necrotic cell death including those induced by DR ligands (40, 41). ROS levels are controlled by the antioxidant defense system, including the antioxidant enzymes manganese- or copper–zinc-containing superoxide dismutase (SOD), which catalyzes the dismutation of O$_2^•$– into H$_2$O$_2$ and catalase and glutathione peroxidase, which degrade H$_2$O$_2$. Thus, the balance between the machinery for ROS generation (prooxidant system) and the machinery for ROS scavenging (antioxidant system) is a critical determinant of whether the cell fate is proliferation or death. Indeed, generation of ROS is also associated with the apoptosis induced by DR ligands such as Fas (42–45) and TNF-α (46, 47). TRAIL has been shown to induce the generation of intracellular ROS, including H$_2$O$_2$, which may be critical in regulating the responses of cancer cells to TRAIL (48). A variety of natural and synthetic compounds capable of increasing the intracellular H$_2$O$_2$ level, including LY35001 (49), wogonin (50), and diallyl polysulfides (51, 52) potentiate TRAIL cytotoxicity toward different human malignant cells (Table 3). Moreover, direct application of H$_2$O$_2$ alone induces apoptosis or potentiates death ligand-induced apoptosis in different cell types (23, 53). In addition, various antioxidants such as N-acetyl-L-cysteine (NAC) and manganese SOD, and catalase block TNF-α- and Fas-induced apoptosis (54, 55). These observations suggest that ROS are important mediators of death ligand-induced apoptosis. Both NADPH oxidase (42, 45, 47) and mitochondria (43, 46) have been implicated as the cellular sources of ROS generated by TNF-α- or Fas-mediated signaling in various cell types. Conversely, ROS or prooxidant conditions are protective under certain circumstances (56). Thus, ROS seem to exhibit both pro-apoptotic and anti-apoptotic functions. Hence, the role of H$_2$O$_2$ in DR-mediated cell death remains controversial. To date there is no general model that can explain the dual role of ROS in apoptosis. However, accumulating evidence suggests that ROS control another form of cell death, autophagy (57, 58), which protects cancer cells against apoptosis. This emerging concept is interesting because it may explain that ROS exert their anti-apoptotic function through the control of cancer cell autophagy. However, this issue is not the focus of the present review, as it has been comprehensively reviewed by others (59–61).

**ROLE OF MITOCHONDRIAL O$_2^•$– IN CANCER CELL APOPTOSIS**

Another possible explanation for the dual role of ROS in TRAIL-induced apoptosis is that different oxidant species mediate reciprocal effects. Indeed, the generation of various ROS and reactive nitrogen species including H$_2$O$_2$, O$_2^•$–, nitric oxide (NO), and peroxynitrite (ONOO–) is associated with selective killing (Tables 1 and 2) and TRAIL-sensitization (Table 3) in cancer cells. To define the oxidant species mediating TRAIL-induced apoptosis in cancer cells, we analyzed ROS generation using 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) and dihydroethidine (DHE) after TRAIL treatment. DCFH-DA is rapidly taken up by cells and hydrolyzed into DCFH by cellular esterase activity. DCFH is then converted into the fluorescent compound DCF by oxidation mediated by H$_2$O$_2$, ONOO–, and •OH, but not O$_2^•$–. Conversely, DHE undergoes two-electron oxidation to form DNA-binding ethidium bromide in a reaction that is relatively specific for O$_2^•$–. Consequently, DCFH-DA and DHE have been widely used to detect intracellular H$_2$O$_2$ and O$_2^•$–, respectively in various cell types (62–64). TRAIL treatment results in the generation of intracellular H$_2$O$_2$ and O$_2^•$– in Jurkat leukemia and A375 melanoma cells (20). The time courses of the generation of these two oxidants are different in that the H$_2$O$_2$ generation is rapid (detected within 30 min) and transient (declining to the basal level within 1 h), while the O$_2^•$– generation is initially detected at 2 h and persistent (increasing for another 2 h), and the latter, but not the former, is correlated with apoptosis. In support of the role of O$_2^•$–, Mn(III)tetrakis(4-benzoic acid)porphin chloride (MnT- BaP), a SOD mimetic that can scavenge O$_2^•$– and ONOO–, but not NO, abolishes TRAIL-induced apoptosis and DHE responses (20). Moreover, analyses using MitoSOX, which is localized to mitochondria and thereby serve as a selective probe for O$_2^•$– in these organelles (65), revealed that TRAIL dose-dependently induces O$_2^•$– generation within the mitochondria, which is blocked by MnTBAP. ONOO– can also oxidize DCFH, and MnTBAP was reported to selectively scavenge ONOO– over O$_2^•$– (66). However, ONOO– seems to play a minor role in TRAIL-induced apoptosis, because: (i) TRAIL induces no substantial NO production for up to at least 4 h; and (ii) synthesized ONOO– causes minimal cell death, although it can dose-dependently cause DCFH oxidation. The observations that MnTBAP blocks TRAIL-induced ΔΨm collapse and caspase-3/7 activation indicate that O$_2^•$– is the main participant in the mitochondrial dysfunction. In addition, MnTBAP reduces TRAIL-induced XBP-1 activation (20). These observations suggest that mitochondrial ROS (mROS) mediate both mitochondrial and ER dysfunctions during TRAIL-induced apoptosis.

Studies on the effects of exogenously applied H$_2$O$_2$ have provided another line of evidence for the role of mROS in mediating apoptosis. Direct application of H$_2$O$_2$ causes apoptosis in TRAIL-resistant melanoma cells and sensitizes these cells to TRAIL (23). The potentiation of apoptosis mainly occurs through the mitochondrial and ER pathways, as shown by ΔΨm collapse, caspase-3/7 activation, GRP-78 downregulation, and XBP-1 activation. Strikingly, after TRAIL treatment, the intracellular H$_2$O$_2$ level increases rapidly (within 10–30 min) but transiently (declining to the basal level at 1 h), while the intracellular O$_2^•$– level increases over time for at least 4 h. MnTBAP, but not catalase, can block the O$_2^•$– increase and apoptosis in parallel, indicating that O$_2^•$– mainly mediates the apoptosis. In addition, a robust increase in MitoSOX signals is observed in parallel with the O$_2^•$– increase and MnTBAP blocks this oxidative response, suggesting an O$_2^•$– increase within the mitochondria. Moreover, H$_2$O$_2$ induces ΔΨm collapse, caspase-3/7 activation, and XBP-1 activation, all of which are blocked by MnTBAP treatment. These observations suggest that exogenously applied H$_2$O$_2$ can stimulate O$_2^•$– generation within...
mitochondria and that the mROS mediate the mitochondrial and ER dysfunctions. In addition, H$_2$O$_2$ causes minimal intracellular and mROS generation in melanocytes in parallel with its minimal cytotoxic effect (23). Taken together, these findings strongly suggest a pro-apoptotic role of mROS in cancer cell apoptosis.

In normal resting cells, 0.1–2% of electrons carried by the mitochondrial electron transport chain (ETC) leak from this pathway and form O$_2^−$. Impaired mitochondrial metabolism causes robust leakage of free electrons, thereby resulting in ROS generation within the organelles. Consequently, mitochondrial metabolic inhibitors serve as powerful tools for studying the role of mROS in a given biological response. Studies using Jurkat cells and A375 melanoma cells as a model have revealed that in both cell types, rotenone, an inhibitor of complex I, is the most potent at inducing apoptosis, while FCCP, a classic uncoupler of oxidative phosphorylation (OXPHOS) is less effective and complex III inhibitor antimycin A is ineffective. However, all of these compounds markedly potentiate TRAIL-induced apoptosis and mROS generation (20, 21). The three metabolic inhibitors can also potentiate TRAIL-induced activation of caspase-3/7 and XBP-1, and both effects are blocked by MnTBA, indicating that mROS generated by the ETC mediate both mitochondrial and ER dysfunctions during TRAIL-induced apoptosis (20). These findings are similar to a previous report that CCCP, another OXPHOS uncoupler, enhances TRAIL-induced apoptosis in TRAIL-resistant human colon carcinoma cell lines (RKO, HT29, and HCT8), while CCCP alone has little effect on apoptosis or release of pro-apoptotic factors from mitochondria (67). CCCP also enhances TRAIL-induced caspase-8, Bid, caspase-9 activation, and Bax conformational change and translocation to mitochondria. CCCP treatment results in the generation of ROS as determined by DHE, and the synergistic effect of CCCP on the TRAIL-induced apoptotic pathway is abrogated by the non-specific ROS scavenger NAC. It is noteworthy that when mitochondria are uncoupled, shRNA-mediated caspase-9 depletion cannot protect the cells against cell death, suggesting modulation of the mode of the caspase cascade. It has been shown that alterations in mitochondrial function, such as OXPHOS, affect the response of tumor cells to apoptosis induced by death ligands including O$_2^−$ generation (68, 69), while death ligands affect mitochondrial metabolism and function. Thus, mitochondrial function and death ligand-induced apoptosis are intimately associated with one another. In this functional relationship, loss of ∆Ψ$_m$, i.e., mitochondrial membrane depolarization (MMD), may play a central role, because it is not only a major cause of mROS generation but also provokes membrane integrity disruption and caspase cascade activation. There is accumulating evidence to suggest that mROS play a key role in MPT induction by affecting the mPTP conformation. First, ROS are byproducts of OXPHOS and excessive ROS generation is potentially deleterious to mitochondrial and cellular functions. Second, ANT has three cysteine residues whose oxidation is critical for mPTP open–closed transitions and Ca$^{2+}$ release from the mitochondrial matrix, and mPTPs are believed to be particularly vulnerable to ROS (30–32). Consequently, the MPT can be triggered by excessive mROS generation and/or disruption of the mitochondrial redox homeostasis (70–73). Third, within mitochondria, cytochrome c is bound to the outer surface of the IMM by its association with the mitochondrial phospholipid cardiolipin, and oxidation of cardiolipin is thought to decrease this contact (74). Thus, oxidation of cardiolipin may also be required to liberate sufficient cytochrome c to trigger caspase activation and induce apoptosis. Consequently, oxidation of cardiolipin may serve as a biochemical hallmark of mitochondrial oxidative stress and apoptosis. As the fluorescent dye 10-N-acridine orange (NAO) binds to the non-oxidized, but not oxidized, form of cardiolipin independently of ∆Ψ$_m$, measurements of NAO fluorescence enable monitoring of the oxidation of cardiolipin in mitochondria (75). It has been shown that in parallel with the increase in MitoSOX signals, TRAIL treatment results in oxidation of cardiolipin in human leukemia and melanoma cells (20, 21). Agonistic antibodies against DR4 and DR5, which trigger the formation of multimeric complexes containing only specific TRAIL-Rs (76, 77) also induce robust cardiolipin oxidation in a dose-dependent manner, indicating that this oxidation is mediated by DR4/DR5 (21). The MPT also results in dissipation of ∆Ψ$_m$ and enhances mROS production via disintegration of the ETC, thereby progressively shutting down OXPHOS and impairing energetic metabolism (78). Hence, the MPT is a rate-limiting and self-amplifying process for apoptosis in which ROS and MMD play key roles. Indeed, MMD is the most common event observed concomitantly with ROS generation in cell death induced by diverse death-inducing stimuli (Tables 1 and 2).

**CROSSTALK BETWEEN MEMBRANE DEPOLARIZATION AND ROS**

Several lines of evidence suggest that membrane depolarization and ROS are intimately associated with one another. First, membrane depolarization controls the generation of ROS via NADPH oxidase activation. In endothelial cells (ECs), it has been shown that loss of fluid shear stress or ischemia results in the generation of ROS associated with the activation of EC NADPH oxidase (79, 80). It has been suggested that this activation of ROS generation is caused by the activation and assembly of NOX2 through phosphoinositide-3-kinase (PI3K)/serine threonine kinase Akt (81). It is noted that the activation of ROS generation is triggered by EC membrane depolarization caused by inactivation of K$_{ATP}$ channels. It is widely accepted that cancer cells express various NOX family members (NOX 1–5, Duox 1, 2) and that these NADPH oxidases play important roles in cancer cell proliferation, death, function, and tumorigenesis (82). For instance, it has been shown that binding of SDF-1α to the chemokine receptor, cysteine (C)-X-C receptor-4, which contributes to the enhanced metastatic functions in prostate cancer cells, promotes ROS generation via NOX2 activation through the PI3K/Akt signaling pathway (83). VEGF that plays a critical role in vascular pathophysiology and induces ROS generation in B16F10 cells, a human leukemia cell line, through activation of NOX2 and NOX4, and the NOX-generated ROS are required to sustain cell viability and proliferation, and prevent apoptosis (84). Second, ROS were shown to regulate the sustained membrane depolarization during tumor cell apoptosis. As mentioned above, inactivation of Na$^+$–K$^+$–ATPase is responsible for the sustained membrane depolarization during Fas-induced apoptosis (14, 15). This Na$^+$–K$^+$–ATPase inactivation was shown to be associated with cleavage of the 42-kDa β subunit and decreased levels of the 110-kDa α subunit (15). Fas ligation also
triggers the internalization of plasma membrane Na\(^{+}\)-K\(^{+}\)-ATPase in tumor and normal cells, which is induced by intracellular glutathione depletion and H\(_2\)O\(_2\) generation (85). A molecular mechanism for the H\(_2\)O\(_2\)-induced internalization of Na\(^{+}\)-K\(^{+}\)-ATPase is considered to be serine phosphorylation of the \(\alpha\)1 subunit and regulation by mitochondrial H\(_2\)O\(_2\) and the anti-apoptotic protein Bcl-2 (15, 85). Collectively, these observations suggest that ROS can control depolarization in malignant cells through the modification, degradation, and inactivation of Na\(^{+}\)-K\(^{+}\)-ATPase. Recently, another crosstalk between depolarization and mROS in cancer cells was suggested. Membrane-depolarizing agents by themselves increase mROS and potentiate TRAIL-induced mROS generation, indicating that depolarization controls mROS (21). It is notable that depolarization increases the surface expression of DR5, the triggering of which increases mROS. Since depolarization potentiates TRAIL-induced activation of the transcription factor XBP-1, which is engaged in the regulation of surface DR5 expression (26), it is possible to speculate that the upregulation of surface DR5 expression results in increased mROS accumulation. However, scavenging of mROS by the antioxidant MnTBaP reduces depolarization, while mROS accumulation caused by mitochondrial metabolic dysfunction potentiates the depolarization (21). Collectively, these observations suggest that depolarization and mROS mutually regulate one another. Figure 1 shows the current model for the potentiation of TRAIL-induced apoptosis in cancer cells by membrane depolarization in connection with ROS.

Several TRAIL-resistant cancer cell types, such as malignant melanoma cells, appear to gain considerable tolerance for oxidative stress-mediated activation of the intrinsic death pathway. However, accumulation of mROS can also promote the formation of unfolded or misfolded proteins, thereby provoking ERS responses such as activation of the transcriptional factor XBP-1. XBP-1 activation leads to upregulation of the surface TRAIL-R2 expression level, thereby enhancing the death signaling. When used together with TRAIL, membrane-depolarizing agents can potentiate mROS accumulation sufficiently to activate not only the intrinsic death pathway, but also the ERS-mediated death pathway, thereby committing drug-resistant cancer cells to apoptosis. Although the precise biochemical and biological consequences between membrane depolarization and mROS generation remain to be elucidated, these two events occur in parallel, indicating that they are intimately associated. Since TRAIL signaling alone can induce sustained depolarization, it is possible that the ROS increase causes this response by inactivating plasma membrane Na\(^{+}\)-K\(^{+}\)-ATPase and/or K\(_{ATP}\) channels.

**Figure 1** The current model for the potentiation of TRAIL-induced apoptosis in cancer cells by depolarization. Triggering of TRAIL-R1 (DR4)/TRAIL-R2 (DR5) induces the generation and accumulation of mROS, leading to impairment of the ETC function and cardiolipin oxidation. Impairment of the ETC complex I/III function decreases H\(^{+}\) efflux, thereby causing \(\Delta\Phi_{m}\) dissipation, i.e., MMD, and additional mROS generation and cardiolipin oxidation, thereby forming a positive loop. Cardiolipin oxidation and \(\Delta\Phi_{m}\) dissipation cooperatively promote the MPT and liberation of sufficient cytochrome c to trigger caspase activation and induce apoptosis. TRAIL-resistant cancer cells appear to gain considerable tolerance for oxidative stress-mediated activation of the intrinsic death pathway. Accumulation of mROS can also promote the formation of unfolded or misfolded proteins, thereby provoking ERS responses such as activation of the transcriptional factor XBP-1. XBP-1 activation leads to upregulation of the surface TRAIL-R2 expression level, thereby enhancing the death signaling. Activation of this alternative death pathway may contribute to commit TRAIL-resistant cancer cells to apoptosis.
Abnormal increases in ROS in cancer cells serves as a target for tumor-selective killing. Cellular oxidative stress (OS) level is regulated by the balance between the machinery for ROS generation (prooxidant system) and the machinery for ROS scavenging (antioxidant system). In normal cells, the antioxidant system is normal and low physiological levels of ROS, which can function as second messengers in intracellular signaling and are required for normal cell function, are generated. Owing to their active metabolism and genetic instability under the control of oncogenic transformation such as prooxidant system and the antioxidant system is a consequence of increased ROS generation and/or decreased antioxidants in cancer cells. Such abnormal increases in ROS makes cancer cells more vulnerable than normal cells to cell damage induced by exogenous ROS-inducing agents and can be exploited to selectively kill cancer cells (96–98) (Figure 2). In this respect, it is noted that diverse natural products and synthetic chemicals that exhibit selective killing effects are capable of inducing intracellular ROS generation (Tables 1 and 2). For instance, β-phenylethyl isothiocyanate (PEITC) is a natural product found in cruciferous vegetables with chemopreventive activity, and has been shown to increase ROS generation and induce apoptosis (99, 100). Moreover, recent work has shown the selective killing of oncogenically transformed cells by PEITC (101–103), supporting the emerging view that an intrinsic excess oxidative stress under the control of oncogenic transformation can be exploited as a cancer-selective target.

CONCLUSION
Recent work has revealed that membrane depolarization is an early and prerequisite event during death ligand-induced apoptosis in malignant cells. Moreover, it has been shown that persistent membrane depolarization can facilitate tumor-selective killing and TRAIL-sensitizing effects by promoting mitochondrial and ER dysfunctions. It is noted that membrane depolarization and ROS regulate one another although the precise mechanisms underlying the mutual regulation remain to be elucidated. The emerging concept is that owing to their active metabolism and genetic instability under the control of oncogenic transformation, cancer cells harbor an excess oxidative stress over normal cells and that this intrinsic oxidative stress can be exploited to selectively kill malignant cells. Thus, the crosstalk is one possible rationale why diverse membrane-depolarizing agents can exhibit tumor-selective killing and TRAIL-sensitizing effects in cancer cells. Since depolarization is intimately linked to not only mitochondrial integrity disruption but also ER dysfunction, and impacts cancer cells selectively, further studies on its role in cancer cell death may afford a novel approach for tumor-selective killing.

REFERENCES
1. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy. Cell Death Differ (2003) 10:66–75. doi:10.1038/sj.cdd.4401187
2. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 8:782–5. doi:10.1038/nrc2465
3. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene (2008) 27:6207–15. doi:10.1038/onc.2008.298
4. Sayers TJ. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother (2011) 60:1173–80. doi:10.1007/s00262-011-1008-4
5. Brost S, Zimmermann A, Koschyn R, Sykora I, Stremmel W, Schirmacher P, et al. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection. Pathol Res Pract (2014) 210:83–91. doi:10.1016/j.prp.2013.10.005

6. Badmann A, Langsch S, Kegoh A, Brunner T, Kaufmann T, Corazza N. TRAIL enhances paracetamol-induced liver sinusoidal endothelial cell death in a Bim- and Bid-dependent manner. Cell Death Dis (2012) 20:3.e447. doi:10.1038/cddr.2012.185

7. Cazzaneve SC, Mott JL, Bronk SE, Werneburg NW, Fingsas CD, Meng XW, et al. Death receptor 5 signaling promotes hepatocyte lipooapoptosis. J Biol Chem (2011) 286:39336–48. doi:10.1074/jbc.M111.280420

8. Corazza N, Jakob S, Schaer C, Frese S, Kegoh A, Stroka D, et al. TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J Clin Invest (2006) 116:2493–9. doi:10.1172/JCI22776

9. Förster A, Preussner LM, Seeger JM, Rabenhorst A, Kashkar H, Mrowietz U, et al. Dimethylfumarate induces apoptosis in human mast cells. Exp Dermatol (2013) 22:719–24. doi:10.1111/exd.12247

10. Dyer MJ, MacFarlane M, Cohen GM. Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol (2007) 25(28):4505–6.

11. Dimberg L, Andersson CK, Camidge R, Behbahani K, Thorburn A, Ford HL. On the TRAIL to successful cancer treatment? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene (2013) 32:1341–50. doi:10.1038/onc.2012.164

12. McCarthy JV, Cotter TG. Cell shrinkage and apoptosis: a role for potassium and sodium ion efflux. Cell Death Differ (1997) 4:756–78. doi:10.1038/sj.cdd.4400286

13. Lang E, Foller M, Lang K, Lang P, Ritter M, Vereninov A, et al. Cell volume regulatory ion channels in cell proliferation and cell death. Methods Enzymol (2007) 428:209–25. doi:10.1016/S0076-6879(07)28011-5

14. Bortner CD, Gomez-Angelats M, Cidlowski JA. Plasma membrane depolarization without repolarization is an early molecular event in anti-Fas-induced apoptosis. J Biol Chem (2001) 276:4304–14. doi:10.1074/jbc.M005171200

15. Yin W, Li X, Feng S, Cheng W, Tang B, Shi YL, et al. Plasma membrane depolarization and Na⁺/K⁺-ATPase impairment induced by mitochondrial toxins augment leukemia cell apoptosis via a novel mitochondrial amplification mechanism. Biochem Pharmacol (2009) 78:191–202. doi:10.1016/j.bcp.2009.03.025

16. Nolte F, Friedrich O, Rójewski M, Fink RH, Schenzenmeyer H, Köper S. Depolarisation of the plasma membrane in the arsenic trioxide (As₂O₃) and anti-CD95-induced apoptosis in myeloid cells. FEBS Lett (2004) 578:85–9. doi:10.1016/j.fsl.2004.07.075

17. Ghoumari AM, Piochon C, Tomkiewicz C, Eychenne B, Levenes C, Dusart I. The permeability transition pore complex in cancer cell death. Oncogene (2006) 25:4744–56. doi:10.1038/sj.onc.1209609

18. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell (2004) 116:205–19. doi:10.1016/S0092-8674(04)00046-7

19. Halestrap AP, Brennert C. The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death. J Med Chem (2003) 46:1507–25. doi:10.2172/928760337257278

20. Lemasters JJ, Theruvath TP, Zhong Z, Nieminen AL. Mitochondrial calcium and the permeability transition in cell death. Biochim Biophys Acta (2009) 1787:1395–401. doi:10.1016/j.bbabio.2009.06.009

21. Zivovotovsky B, Galiulli L, Kepp O, Kroemer G. Adenine nucleotide translocase: a component of the phylogenetically conserved cell death machinery. Cell Death Differ (2009) 16:1419–25. doi:10.1038/cdd.2009.118

22. Dalla Via L, Garcia-Aragon AN, Martinez-Vazquez M, Grancca S, Martinis P, Toninelli A. Mitochondrial permeability transition as target of anticancer drugs. Curr Pharm Des (2014) 20:223–44.

23. Gogvadze V. Targeting mitochondria in fighting cancer. Curr Pharm Des (2011) 17:4034–46.

24. Boyce M, Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ (2006) 13:363–73. doi:10.1038/sj.cdd.4401871

25. Szegedi E, Fitzgerald U, Samali A. Caspase-12 and ER-stress-mediated apopto- sis: the story so far. Ann N Y Acad Sci (2003) 1010:886–94. doi:10.1196/annals.1299.032

26. Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol (2004) 14:20–8. doi:10.1016/j.tcb.2003.11.001

27. Groenendyk J, Michaelak M. Endoplasmic reticulum quality control and apoptosis. Acta Biochim Pol (2005) 52:881–95.

28. Martin S, Hill DS, Paton JC, Paton AW, Birch-Machin MA, Lovat PE, et al. Targeting GRP78 to enhance melanoma cell death. Pigment Cell Melanoma Res (2005) 18:675–82. doi:10.1111/j.1755-148X.2010.00731.x

29. Shen HM, Pervaiz S. TNF receptor superfamily-induced cell death: redox-dependent execution. J Cell Biochem (2006) 98:2159–88. doi:10.1002/jcb.20363

30. Circi ML, Aw TY. Reactive oxygen species, cellular redox systems, and apop- tosis. Free Radic Biol Med (2010) 48:749–62. doi:10.1016/j.freeradbiomed.2009.12.022

31. Suzuki-Karasaki M, Ochiai T, Suzuki-Karasaki Y. Crosstalk between mitochondria and endoplasmic reticulum dysfunctions in TRAIL-induced apoptosis in Jurkat cells. Free Radic Biol Med (2015) 61:273–84. doi:10.1016/j.freeradbiomed.2013.04.020

32.署名作者等。Depolarization controls tumor-selective killing.
cell death by the electron flux through the electron transport chain complex I. Antioxid Redox Signal (1999) 2:285–95. doi:10.1089/ars.1999.1.3-285.

47. Kim YS, Morgan MJ, Choksi S, Liu ZG. TNF-α-induced activation of the Non1 NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell (2007) 26:675–87. doi:10.1016/j.molcel.2007.04.021

48. Mellier G, Pervez S. The three Rs along the TRAIL: resistance, re-sensitisation and reactive oxygen species (ROS). Free Radic Res (2012) 46:996–1003. doi:10.3109/10724629.2012.690514

49. Shenoy K, Wu Y, Pervez S. LA303511 enhances TRAIL sensitivity of SHSY-5Y neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. Cancer Res (2009) 69:1941–50. doi:10.1158/0008-5472.CAN-08-1996

50. Lee DH, Rhee JG, Lee YI. Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin. Br J Pharmacol (2009) 157:1189–202. doi:10.1111/j.1476-5381.2009.02425.x

51. Das A, Banik NL, Ray SK. Garlic compounds generate reactive oxygen species leading to activation of stress kinases and cysteine proteases for apoptosis in human glioblastoma T98G and U87MG cells. Cancer (2007) 110:1083–95. doi:10.1002/cncr.223888

52. Powolny AA, Singh SY. Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. Cancer Lett (2008) 269:305–14. doi:10.1016/j.canlet.2008.05.027

53. Pallepiti PA, Avellin-Bates DA. Activation of ER stress and apoptosis by hydrogen peroxide in HeLa cells: protective role of mild heat preconditioning at 40°C. Biochim Biophys Acta (2011) 1813:1987–99. doi:10.1016/j.bbamcr.2011.07.021

54. Delhalle S, Derszewski V, Benoit V, Merveille MP, Bours V, NP-kappa-dependent MnSOD expression protects adenocarcinoma cells from TNF-α-induced apoptosis. Oncogene (2002) 21:3917–24. doi:10.1038/sj.onc.1205489

55. Perez-Cruz I, Carcamo JM, Golde DW. Vitamin C inhibits FAS-induced apoptosis. Cell Death Differ (2009) 16:1040–52. doi:10.1038/cdd.2009.49

56. Wang Y, Nartiss Y, Steipe B, McQuibban GA, Kim PK. ROS-induced mitochondrial superoxide production in live cells. J Leukoc Biol (2013) 93:1263–5. doi:10.4161/auto.25233

57. Al-Mehdi AB, Zhao G, Dodia C, Tozawa K, Costa K, Muzykantov V, et al. Endothelial NADPH oxidase producing mitochondria and cell. J Biol Chem (2007) 282:7436–45. doi:10.1074/jbc.M60210.2005

58. Bonner MY, Arbiser JL. Targeting NADPH oxidases for the treatment of cancer and inflammation. Frontiers in Oncology | Molecular and Cellular Oncology | May 2014 | Volume 4 | Article 128 | 12

59. Orrenius S. Reactive oxygen species in mitochondria-mediated cell death. Drug Metab Rev (2007) 39:443–55. doi:10.1080/03602530701465316

60. Ott M, Gogadze V, Orrenius S, Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis (2007) 12:913–22. doi:10.1007/s10495-007-0756-2

61. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Moreno-Sánchez R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med (2010) 31:29–59. doi:10.1016/j.mam.2009.12.006

62. Devadas S, Zaridze G, Arbiser JL. Targeting NADPH oxidases for the treatment of cancer and inflammation. Cell Death Differ (2007) 14:1243–7. doi:10.1038/sj.cdd.4042135

63. Kim YS, Morgan MJ, Choksi S, Liu ZG. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell (2009) 46:2209–9. doi:10.1016/j.molcem.2009.04.013

64. Mukhopadhyay P, Rajesh M, Yoshihiro K, Haskó G, Pacher P. Simple quantitative detection of mitochondrial superoxide production in live cells. Biochem Biophys Res Commun (2007) 358:203–8. doi:10.1016/j.bbrc.2007.04.106

65. Batinic-Haberl E, Cuzzocrea S, Reboças JS, Ferrer-Sueta G, Mazzeno E, Di Paola R, et al. Pure MnTfTRAP selectively scavenges peroxynitrite over superoxide: comparison of pure and commercial MnTfTRAP samples to MnTE-2Py in two models of oxidative stress injury, an SOD-specific Escherichia coli model and carrageenan-induced pleurisy. Free Radic Biol Med (2009) 46:192–201. doi:10.1016/j.freeradbiomed.2008.09.042
apoptosis mediated by glutathione depletion and generation of hydrogen peroxide. 

Leukemia (2007) 21:1669–78. doi:10.1038/sj.leu.2404791

86. Sztroinski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res (1991) 51:794–8.

87. Akpin-Chen Y, Ahmad IM, Zhu Y, Oberley DW, Spitn DJ. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. J Biochem (2009) 418:29–37. doi:10.1042/Bj20081258

88. Hyu Y, Rosen DG, Zhou Y, Fang L, Yang G, Liu J, et al. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem (2005) 280:39485–92. doi:10.1074/jbc.M503296200

89. Radosky DC, Levy DJ, Littlepage LE, Liu H, Nelson CM, Fata JE, et al. Rac1b and reactive oxygen species mediate MMP-3 induced EMT and genomic instability. Nature (2005) 436:123–7. doi:10.1038/nature03688

90. Irama K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science (1997) 276:1649–52. doi:10.1126/science.276.5306.1649

91. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem (2000) 275:24273–8. doi:10.1074/jbc.M002942000

92. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, et al. c-Myc can induce growth inhibition of cancer cells. Mol Cancer Ther (2003) 2:402–8. doi:10.1124/mol.102.032458

93. Behrend L, Henderson G, Zwacka RM. Reactive oxygen species in oncogene-induced genetic instability. J Cell Biochem (2010) 111:1629–41. doi:10.1002/jcb.22898

94. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, et al. Selective killing of cancer cell mitochondria and reduces growth of human colon tumor xenografts. Mol Cancer Ther (2011) 10:57–67. doi:10.1158/1535-7163.MCT-10-0735

95. Macho A, Calzado MA, Muñoz-Blanco J, Gómez-Díaz C, Gajate C, Mollinedo F, et al. Selective induction of apoptosis by caspase in transformed cells: the role of reactive oxygen species and calcium. Cell Death Differ (1999) 6:155–65. doi:10.1038/sj.cdd.4400465

96. Fong YC, Lee CY, Jin TR, Li TM, et al. Epigallocatechin-3-gallate induces cell apoptosis of human chondrosarcoma cells through apoptosis signal-regulating kinase 1 pathway. J Cell Biochem (2011) 112:1601–11. doi:10.1002/jcb.23072

97. Shimizu H, Tong Y, Zhou Y, Feng L, Yang G, Liu J, et al. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem (2005) 280:39485–92. doi:10.1074/jbc.M503296200

98. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, et al. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/flox-mediated activation of mitochondrial pathway. Mol Cancer Ther (2006) 5:1873–82. doi:10.1158/1535-7163.MCT-06-0863

99. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-induced apoptosis. J Cell Biochem (2010) 111:1629–41. doi:10.1002/jcb.22898
